BFM
FENC icon

Boothbay Fund Management’s Fennec Pharmaceuticals FENC Stock Holding History

Boothbay Fund Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,818
Closed -$90K – 1956
2023
Q1 		$90K Buy
+10,818
New +$100K ﹤0.01% 1965

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Boothbay Fund Management's FENC Position: Q2 2023 in Review

Boothbay Fund Management sold out of Fennec Pharmaceuticals (FENC) in Q2 2023, closing a stake of 10,818 shares — an estimated $90K sold.

Boothbay Fund Management first reported a position in FENC in Q1 2023 and held it in 1 quarter. The position peaked at $90K in Q1 2023. 56 funds tracked by Wall St. Rank hold FENC as of Q2 2023.

  • Boothbay Fund Management reported no remaining Fennec Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 10,818 Fennec Pharmaceuticals shares in Q2 2023, an estimated $90K.
  • Boothbay Fund Management first reported a position in Fennec Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Boothbay Fund Management's Fennec Pharmaceuticals position peaked at $90K in Q1 2023.
  • 56 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.